ImmuCell Corporation (ICCC) News

ImmuCell Corporation (ICCC): $3.69

0.03 (+0.82%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add ICCC to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#NR of 481

in industry

Filter ICCC News Items

ICCC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ICCC News From Around the Web

Below are the latest news stories about IMMUCELL CORP that investors may wish to consider to help them evaluate ICCC as an investment opportunity.

ImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good day, everyone, and welcome to the ImmuCell Corporation’s Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. And now I would like to turn the conference over to Joe Diaz. Please go ahead. Joe Diaz: […]

Yahoo | November 15, 2023

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023. Management’s Discussion: “Our unaudited, preliminary product sales for the third quarter of 2023 were first

Yahoo | November 13, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2023 after the market closes on Monday, Novemb

Yahoo | November 7, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023. Preliminary, Unaudited Total Sales Results: 20232022$ Increase ($ Decrease) % Incr

Yahoo | October 5, 2023

ImmuCell Announces Submission of CMC Technical Section to the FDA

PORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA. On August 10, 2023, the Company issued a disclosure stating that

Yahoo | August 29, 2023

Q2 2023 ImmuCell Corp Earnings Call

Q2 2023 ImmuCell Corp Earnings Call

Yahoo | August 12, 2023

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023. Management’s Discussion: “Our unaudited, preliminary product sales were first reported on July 11, 2023,” comment

Yahoo | August 10, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ETPORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2

Yahoo | August 7, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

PORTLAND, Maine, July 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023. Preliminary, Unaudited Total Sales Results: 20232022($ Decrease) (% Decrease)During th

Yahoo | July 11, 2023

ImmuCell Announces Change in Timing of Anticipated FDA Submission

PORTLAND, Maine, June 28, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule. “Although we had planned to make our next FDA submission during the second quarter of this year, we have decided to add one addit

Yahoo | June 28, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!